GLP-1 receptor agonists linked to significantly lower dementia rates in diabetic patients, with ongoing Alzheimer's trials

Alzheimer's disease (AD) is a leading cause of death and the most common form of dementia, with prevalence projected to triple by 2050. Current treatments like cholinesterase inhibitors and NMDA receptor antagonists only offer symptomatic relief, failing to halt disease progression. This critical gap necessitates the development of effective disease-modifying therapies. Repurposing existing drugs with established safety profiles is a promising strategy, particularly for complex neurodegenerative conditions where novel drug development is challenging.

This paper synthesizes existing evidence regarding glucagon-like peptide-1 receptor agonists (GLP-1 RA) for Alzheimer's disease. It references pooled data from three randomized, double-blind, placebo-controlled trials involving 15,820 patients with type 2 diabetes, comparing GLP-1 RA treatment against placebo. Additionally, it draws upon a nationwide Danish registry-based cohort study encompassing 120,054 patients to assess the impact of increased GLP-1 RA exposure on dementia incidence. The paper also highlights ongoing clinical trials, EVOKE and EVOKE Plus, investigating semaglutide in patients with early Alzheimer's disease.

Pooled data from three randomized controlled trials demonstrated that GLP-1 receptor agonists significantly reduced the incidence of dementia in type 2 diabetic patients compared to placebo, with a hazard ratio (HR) of 0.47. This indicates a substantial 53% lower risk of dementia. > A nationwide Danish registry-based cohort study further supported these findings, reporting a hazard ratio of 0.89 for dementia incidence with yearly increased exposure to GLP-1 RAs in 120,054 patients. The combined analysis included 15,820 patients from the randomized trials and 120,054 patients from the cohort. The paper also notes that semaglutide, a GLP-1 RA currently under investigation, shares 94% similarity with naturally occurring human GLP-1 hormone, suggesting its potential for similar therapeutic effects.